News

ADI’s Diego Aguilar and Nick House attend the Alzheimer's Association International Conference in Philadelphia (USA), delivering key insights, conducting vital meetings and advocating for care in the era of new treatments.

The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.

Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease.  Donanemab is the…

Regional Director for the Americas, Diego Aguilar, alongside politician and neuroscientist Facundo Manes, and ADI’s Argentinian member association A.L.M.A, joined for urgent action on dementia following steeply increasing dementia forecasts and stalling progress towards a National Dementia Plan in the country.

In recent events, ADI Regional Director for Asia-Pacific, DY Suharya, was invited to contribute to key summits, events and meetings, with a key focus on improving dementia care, innovating dementia technology and advising on advocacy across the Asia-Pacific region and beyond.

ADI is sharing a round-up of our recent action in Europe, on advocacy and research, with ADI Board Vice Chair, Meera Pattabiraman, and ADI Director of Research and Publications, Wendy Weidner. Both taking part in vital dialogues in June 2024. 

In under a year, Brazil has made giant leaps in the development of its own National Dementia Plan, culminating in legislation signed by President  Luiz Inácio Lula da Silva on 4 June, 2024. ADI revisits the journey that we have shared with our Brazilian member association, Febraz, to help make this plan a reality.